Department of Internal Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100010, China.
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100010, China.
J Tradit Chin Med. 2024 Dec;44(6):1177-1186. doi: 10.19852/j.cnki.jtcm.2024.06.006.
To evaluate the effect of Weichang'an pill (, WCAP) on functional dyspepsia (FD) and explore its regulation of brain-gut peptides (BGPs) and gut microbiota balance as a potential treatment mechanism.
The "0 ℃ saline gavage + irregular feeding and tail clamp" method was used to establish the FD rat model, excluding the normal group. The successfully established FD rat models were randomly divided into the model group and the WCAP1 (WC1), WCAP2 (WC2), WCAP3 (WC3), WCAP4 (WC4), WCAP5 (WC5), and Domperidone (Dom) groups ( 10 per group). The unhandled rats were designated as the control group. The gastrointestinal motility of the rats was evaluated using the charcoal propulsion test. Histopathology was assessed by hematoxylin and eosin (HE) staining. The enzyme-linked immunosorbnent assay method was used to detect the levels of motilin (MTL), gastrin (GAS), vasoactive intestinal peptide (VIP), and somatostatin (SS) in the serum from each group. In addition, the gut microbiota composition of fecal samples was analyzed using 16S rRNA sequencing.
Rat models were successfully established according to data from rat state, gastrointestinal motility assessments, and HE staining. WCAP improved FD symptoms by accelerating the gastric emptying and small intestinal transit of FD rats. Mechanistically, WCAP increased the levels of GAS and MTL and reduced the levels of VIP and SS. Moreover, WCAP treatment restored the total relative abundance of Firmicutes and Bacteroidetes, increased the species richness of the gut flora, and modulated the changes in the composition and function of the gut microbiota.
WCAP can effectively promote the recovery of gastrointestinal motility disorders in FD rats. The mechanism may be related to regulating the secretion of BGPs and the composition of the gut microbiota.
评价胃肠安丸（WCAP）对功能性消化不良（FD）的疗效，并探讨其对脑肠肽（BGP）和肠道微生物平衡的调节作用，以期为其提供潜在的治疗机制。
采用“0℃生理盐水灌胃+不定时夹尾刺激”法建立 FD 大鼠模型，剔除正常组。将成功建立的 FD 大鼠模型随机分为模型组和 WCAP1（WC1）、WCAP2（WC2）、WCAP3（WC3）、WCAP4（WC4）、WCAP5（WC5）和多潘立酮（Dom）组（每组 10 只）。未处理的大鼠被指定为对照组。采用炭末推进实验评价大鼠胃肠动力。采用苏木精-伊红（HE）染色法评估组织病理学变化。采用酶联免疫吸附试验法检测各组大鼠血清中胃动素（MTL）、胃泌素（GAS）、血管活性肠肽（VIP）和生长抑素（SS）的水平。此外，采用 16S rRNA 测序法分析粪便样本中的肠道微生物组成。
根据大鼠状态、胃肠动力评估和 HE 染色数据，成功建立了大鼠模型。WCAP 通过加速 FD 大鼠的胃排空和小肠转运，改善了 FD 症状。机制上，WCAP 增加了 GAS 和 MTL 的水平，降低了 VIP 和 SS 的水平。此外，WCAP 治疗恢复了厚壁菌门和拟杆菌门的总相对丰度，增加了肠道菌群的物种丰富度，并调节了肠道菌群的组成和功能变化。
WCAP 可有效促进 FD 大鼠胃肠动力障碍的恢复。其机制可能与调节 BGP 分泌和肠道微生物组成有关。
